脊髄損傷修復のための赤色光治療が節目を通過(Red light therapy for repairing spinal cord injury passes milestone)

ad

2024-05-06 バーミンガム大学

バーミンガム大学の研究チームは、赤色および近赤外光を用いた治療法が脊髄損傷(SCI)患者の神経修復に有効であることを発見しました。この方法は、損傷部位に直接光を照射し、神経細胞の生存率と再生を促進します。研究では、660nmの光を1日1分、5日間照射すると細胞の生存率が45%向上し、動物モデルでも組織瘢痕の減少と機能回復が確認されました。現在、研究チームはこの技術を人間用に開発するための商業パートナーや投資家を求めており、将来的には手術中にデバイスを埋め込むことで脊髄の保護と修復が可能になると期待されています。

<関連情報>

脊髄損傷後の神経再生と失われた機能の回復を促進する埋め込み型および経皮的光バイオモジュレーション Implantable and transcutaneous photobiomodulation promote neuroregeneration and recovery of lost function after spinal cord injury

Andrew R. Stevens, Mohammed Hadis, Alice Phillips, Abhinav Thareja, Michael Milward, Antonio Belli, William Palin, David J. Davies, Zubair Ahmed
Bioengineering & Translational Medicine  Published: 25 April 2024
DOI:https://doi.org/10.1002/btm2.10674

脊髄損傷修復のための赤色光治療が節目を通過(Red light therapy for repairing spinal cord injury passes milestone)

Abstract

Spinal cord injury (SCI) is a cause of profound and irreversible damage, with no effective therapy to promote functional recovery. Photobiomodulation (PBM) may provide a viable therapeutic approach using red or near-infrared light to promote recovery after SCI by mitigating neuroinflammation and preventing neuronal apoptosis. Our current study aimed to optimize PBM dose regimens and develop and validate the efficacy of an invasive PBM delivery paradigm for SCI. Dose optimization studies were performed using a serum withdrawal model of injury in cultures of primary adult rat dorsal root ganglion neurons (DRGN). Implantable and transcutaneous PBM delivery protocols were developed and validated using cadaveric modeling. The efficacy of PBM in promoting recovery after SCI in vivo was studied in a dorsal column crush injury model of SCI in adult rats. Optimal neuroprotection in vitro was achieved between 4 and 22 mW/cm2. 11 mW/cm2 for 1 min per day (0.66 J/cm2) increased cell viability by 45% over 5 days (p <0.0001), increasing neurite outgrowth by 25% (p <0.01). A method for invasive application of PBM was developed using a diffusion-tipped optogenetics fiber optic. Delivery methods for PBM were developed and validated for both invasive (iPBM) and noninvasive (transcutaneous) (tcPBM) application. iPBM and tcPBM (24 mW/cm2 at spinal cord, 1 min per day (1.44 J/cm2) up to 7 days) increased activation of regeneration-associated protein at 3 days after SCI, increasing GAP43+ axons in DRGN from 18.0% (control) to 41.4% ± 10.5 (iPBM) and 45.8% ± 3.4 (tcPBM) (p <0.05). This corresponded to significant improvements at 6 weeks post-injury in functional locomotor and sensory function recovery (p <0.01), axonal regeneration (p <0.01), and reduced lesion size (p <0.01). Our results demonstrated that PBM achieved a significant therapeutic benefit after SCI, either using iPBM or tcPBM application and can potentially be developed for clinical use in SCI patients.

Translational Impact Statement

Photobiomodulation (PBM) may improve recovery after spinal cord injury (SCI) yet delivery of PBM to the injured spinal cord is limited by overlying tissue when applying PBM through the skin. We show the development and use of an implantable device for application of PBM which addresses this problem. Our results demonstrated that implantable PBM improved regeneration of neurons and these doses of PBM also improved functional recovery. This device has the potential to be developed to deliver PBM aimed at improving recovery in patients with SCI.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました